ScreenPoint, Medical

ScreenPoint Medical Hits New Milestones

07.08.2025 - 18:07:14 | prnewswire.co.uk

ScreenPoint Medical Austria Belgium France Germany Italy Netherlands Spain Switzerland United States of America United Kingdom

in August demonstrating that Transpara combined with two other measures delivered a superior short term risk measure relative to many current models (i.e., Gail, TC8). (see attached figure)

"As the most widely utilized Breast AI in clinical practice with 5 million mammograms and 1 million tomosynthesis exams analyzed, we are very proud that study after study continues to demonstrate the value that Transpara brings to breast health care provider and patients. Regardless of country, patient age, breast density, or patient ethnic background, Transpara delivers consistent results. Our in-development offerings will continue to expand the reach and impact of Transpara Portfolio in helping radiologists detect cancer earlier and safely reduce workload," said Mark Koeniguer, ScreenPoint Medical CEO.

Transpara is FDA cleared and has European regulatory approval (CE Mark) for use with 2D and 3D mammography from multiple manufacturers. Used by hundreds of leading centers in more than 30 countries, Transpara is designed to work concurrently with radiologists. Research shows that up to 45% of interval cancers can be found earlier using Transpara, while helping to reduce workload and optimize workflow.

About ScreenPoint Medical

ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment. Transpara is trusted by radiologists globally because it has been developed by experts in machine learning and image analysis and updated with user feedback from world-renowned breast imagers. See all the proof at: https://screenpoint-medical.com/published-evidence/peer-reviewed-publications 

Photo - https://mma.prnewswire.com/media/2282337/Lauritzen_2023_Summary.jpg
Logo - https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg

 

ScreenPoint Medical Logo

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/screenpoint-medical-hits-new-milestones-301994211.html

So schätzen die Börsenprofis Aktien ein!

<b>So schätzen die Börsenprofis   Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | boerse | 67946375 |